WC36 is a novel nonlipidic ингибитор of the липид-SH2 domain interaction. WC36 is effective against RAS-mutated HL-60 AML cells that shows de novo resistance to entospletinib.
WC36 is a novel nonlipidic inhibitor of the lipid-SH2 domain interaction. WC36 is effective against RAS-mutated HL-60 AML cells that shows de novo resistance to entospletinib.
Только для научно-исследовательского применения. Не предназначено для использования у пациентов или в качестве лекарственного средства.